본문 바로가기
KERD
논문KCI 등재

Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor

강윤구|류민희|김경미|양한광|구동회|Lin Shen|Li-Tzong Chen|Akira Sawaki|Seiichi Hirota|Jie Zheng|Bo Zhang|Chin-Yuan Tzen|Chun-Nan Yeh|Toshirou Nishida
대한암학회 (Korean Cancer Association)|2016.10|Cancer Research and Treatment|제48권 제4호|pp. 1155-1166

2

조회

0

다운로드

10

인용

0

참고문헌

키워드

GuidelineRegorafenibGastrointestinal stromal tumorsImatinib mesylateSunitinib
주제분류의학일반

초록

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors originating in the gastrointestinal tract. With the introduction of molecular-targeted therapy for GISTs which has yielded remarkable outcomes, these tumors have become a model of multidisciplinary oncological treatment. Although Western clinical guidelines are available for GISTs, such as those published by the National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO), the clinical situations in Asian countries are different from those in Western countries in terms of diagnostic methods, surgical approach, and availability of new targeted agents. Accordingly, we have reviewed current versions of several GIST guidelines published by Asian countries (Japan, Korea, China, and Taiwan) and the NCCN and ESMO and discussed the areas of dissensus. We here present the first version of the Asian GIST consensus guidelines that were prepared through a series of meetings involving multidisciplinary experts in the four countries. These guidelines provide an optimal approach to the diagnosis and management of GIST patients in Asian countries.

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors originating in the gastrointestinal tract. With the introduction of molecular-targeted therapy for GISTs which has yielded remarkable outcomes, these tumors have become a model of multidisciplinary oncological treatment. Although Western clinical guidelines are available for GISTs, such as those published by the National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO), the clinical situations in Asian countries are different from those in Western countries in terms of diagnostic methods, surgical approach, and availability of new targeted agents. Accordingly, we have reviewed current versions of several GIST guidelines published by Asian countries (Japan, Korea, China, and Taiwan) and the NCCN and ESMO and discussed the areas of dissensus. We here present the first version of the Asian GIST consensus guidelines that were prepared through a series of meetings involving multidisciplinary experts in the four countries. These guidelines provide an optimal approach to the diagnosis and management of GIST patients in Asian countries.

참고문헌 (75)

  1. Corless CL, "Gastrointestinal stromal tumours : origin and molecular oncology", Nat Rev Cancer, 11, pp.865~878 (2011)
  2. "NCCN clinical practice guidelines in oncology: soft tissue sarcoma, version 1" (2015)[URL]
  3. ESMO, "European Sarcoma Network Working Group", Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2014, pp.25(3), 21~26
  4. 강윤구, "Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea", Cancer Research and Treatment, 44(2), pp.85~96 (2012), 대한암학회[DOI]
  5. Nishida T, "Clinical practice guidelines for gastrointestinal stromal tumor(GIST)in Japan : English version", Int J Clin Oncol, 13, pp.416~430 (2008)
  6. Expert Committee on Gastrointestinal Stromal Tumors, CSCO, "China consensus on diagnosis and treatment of gastrointestinal stromal tumors(2013)", Chin Clin Oncol, 18, pp.1025~1034 (2013)
  7. Yeh CN, "Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan", World J Surg Oncol, 10, pp.246~ (2012)
  8. Kyoung-Mee Kim, "Gastrointestinal Stromal Tumors in Koreans:It's Incidence and the Clinical,Pathologic and Immunohistochemical Findings", Journal of Korean Medical Science, 20(6), pp.977~984 (2005), 대한의학회
  9. Demetri GD, "NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors", J Natl Compr Canc Netw, 8(2), pp.1~41 (2010)
  10. Heinrich MC, "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor", J Clin Oncol, 21, pp.4342~4349 (2003)
  11. Fletcher CD, "Diagnosis of gastrointestinal stromal tumors : a consensus approach", Hum Pathol, 33, pp.459~465 (2002)
  12. Liegl B, "Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes", Am J Surg Pathol, 33, pp.437~446 (2009)
  13. Kang GH, "DOG1 and PKC-theta are useful in the diagnosis of KITnegative gastrointestinal stromal tumors", Mod Pathol, 24, pp.866~875 (2011)
  14. Kim KM, "PKCtheta expression in gastrointestinal stromal tumor", Mod Pathol, 19, pp.1480~1486 (2006)
  15. Debiec-Rychter M, "KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours", Eur J Cancer, 42, pp.1093~1103 (2006)
  16. Gao J, "C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients", Med Oncol, 29, pp.3039~3045 (2012)
  17. Kang HJ, "Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors(GIST) : The Korean GIST Study Group(KGSG)study", Acta Oncol, 51, pp.528~536 (2012)
  18. Miranda C, "KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors", Clin Cancer Res, 18, pp.1769~1776 (2012)
  19. Oudijk L, "SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors", Mod Pathol, 26, pp.456~463 (2013)
  20. Janeway KA, "Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations", Proc Natl Acad Sci U S A, 108, pp.314~318 (2011)
  21. Miettinen M, "Succinate dehydrogenase-deficient GISTs : a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age", Am J Surg Pathol, 35, pp.1712~1721 (2011)
  22. Miettinen M, "Gastrointestinal stromal tumors : pathology and prognosis at different sites", Semin Diagn Pathol, 23, pp.70~83 (2006)
  23. Joensuu H, "Risk stratification of patients diagnosed with gastrointestinal stromal tumor", Hum Pathol, 39, pp.1411~1419 (2008)
  24. Rutkowski P, "Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour : the impact of tumour rupture on patient outcomes", Eur J Surg Oncol, 37, pp.890~896 (2011)
  25. Joensuu H, "Risk of recurrence of gastrointestinal stromal tumour after surgery : an analysis of pooled population-based cohorts", Lancet Oncol, 13, pp.265~274 (2012)
  26. Yanagimoto Y, "Re-appraisal of risk classifications for primary gastrointestinal stromal tumors(GISTs)after complete resection : indications for adjuvant therapy", Gastric Cancer, 18, pp.426~433 (2015)
  27. Blay JY, "Consensus meeting for the management of gastrointestinal stromal tumors : report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO", Ann Oncol, 16, pp.566~578 (2005)
  28. Ryu MH, "Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate", Jpn J Clin Oncol, 36, pp.17~24 (2006)
  29. Gold JS, "Combined surgical and molecular therapy : the gastrointestinal stromal tumor model", Ann Surg, 244, pp.176~184 (2006)
  30. Dumonceau JM, "Indications, results, and clinical impact of endoscopic ultrasound(EUS)-guided sampling in gastroenterology : European Society of Gastrointestinal Endoscopy(ESGE)Clinical Guideline", Endoscopy, 43, pp.897~912 (2011)
  31. Iwahashi M, "Surgical management of small gastrointestinal stromal tumors of the stomach", World J Surg, 30, pp.28~35 (2006)
  32. McCarter MD, "Microscopically positive margins for primary gastrointestinal stromal tumors : analysis of risk factors and tumor recurrence", J Am Coll Surg, 215, pp.53~59 (2012)
  33. Novitsky YW, "Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors", Ann Surg, 243, pp.738~745 (2006)
  34. Koh YX, "A systematic review and meta-analysis comparing laparoscopic versus open gastric resections for gastrointestinal stromal tumors of the stomach", Ann Surg Oncol, 20, pp.3549~3560 (2013)
  35. DeMatteo RP, "Two hundred gastrointestinal stromal tumors : recurrence patterns and prognostic factors for survival", Ann Surg, 231, pp.51~58 (2000)
  36. Joensuu H, "Gastrointestinal stromal tumor : a method for optimizing the timing of CT scans in the follow-up of cancer patients", Radiology, 271, pp.96~103 (2014)
  37. Desai J, "Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors", Clin Cancer Res, 13(18 Pt 1), pp.5398~5405 (2007)
  38. Raut CP, "Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors", J Clin Oncol, 24, pp.2325~2331 (2006)
  39. Sym SJ, "Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)", J Surg Oncol, 98, pp.27~33 (2008)
  40. Du CY, "Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib : a prospective randomised trial in China", Eur J Cancer, 50, pp.1772~1778 (2014)
  41. Park SJ, "The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses", Ann Surg Oncol, 21, pp.4211~4217 (2014)
  42. An HJ, "The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST", Ann Surg Oncol, 20, pp.4212~4218 (2013)
  43. Dematteo RP, "Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour : a randomised, double-blind, placebo-controlled trial", Lancet, 373, pp.1097~1104 (2009)
  44. Li J, "Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor", Eur J Surg Oncol, 37, pp.319~324 (2011)
  45. Joensuu H, "One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor : a randomized trial", JAMA, 307, pp.1265~1272 (2012)
  46. Agaimy A, "Gastrointestinal manifestations of neurofibromatosis type 1(Recklinghausen's disease) : clinicopathological spectrum with pathogenetic considerations", Int J Clin Exp Pathol, 5, pp.852~862 (2012)
  47. Bumming P, "Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours(GIST)with imatinib : a centre-based study of 17 patients", Br J Cancer, 89, pp.460~464 (2003)
  48. 오지선, "Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach: Report of Three Cases", Cancer Research and Treatment, 38(3), pp.179~183 (2006), 대한암학회
  49. Prior JO, "Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor", J Clin Oncol, 27, pp.439~445 (2009)
  50. Kim TW, "Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors", Oncologist, 14, pp.540~547 (2009)
  51. Yeh CN, "Kinase mutations and imatinib mesylate response for 64Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital", Ann Surg Oncol, 14, pp.1123~1128 (2007)
  52. "Imatinib dose escalation to 800 mg/day in Korean patients with metastatic or unresectable GIST harboring KIT exon 9mutation (NCT01541709)" (2015)[URL]
  53. Guilhot F, "Indications for imatinib mesylate therapy and clinical management", Oncologist, 9, pp.271~281 (2004)
  54. Blay JY, "Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group", J Clin Oncol, 25, pp.1107~1113 (2007)
  55. Lee JL, "Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response", Jpn J Clin Oncol, 36, pp.704~711 (2006)
  56. Le Cesne A, "Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial", Lancet Oncol, 11, pp.942~949 (2010)
  57. Choi H, "CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment : a quantitative analysis correlated with FDG PET findings", AJR Am J Roentgenol, 183, pp.1619~1628 (2004)
  58. Choi H, "Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate : proposal of new computed tomography response criteria", J Clin Oncol, 25, pp.1753~1759 (2007)
  59. Heinrich MC, "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor", J Clin Oncol, 26, pp.5352~5359 (2008)
  60. Yeh CN, "Surgical management in metastatic gastrointestinal stromal tumor(GIST)patients after imatinib mesylate treatment", J Surg Oncol, 102, pp.599~603 (2010)
  61. Zalcberg JR, "Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg", Eur J Cancer, 41, pp.1751~1757 (2005)
  62. Park I, "Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor", Jpn J Clin Oncol, 39, pp.105~110 (2009)
  63. Yoo C, "Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800mg", day in patients with advanced gastrointestinal stromal tumors, 2013, pp.31, 1367~1374
  64. Demetri GD, "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial", Lancet, 368, pp.1329~1338 (2006)
  65. George S, "Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure", Eur J Cancer, 45, pp.1959~1968 (2009)
  66. Li J, "Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or-intolerant gastrointestinal stromal tumors", Future Oncol, 8, pp.617~624 (2012)
  67. Chu TF, "Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib", Lancet, 370, pp.2011~2019 (2007)
  68. Torino F, "Hypothyroidism related to tyrosine kinase inhibitors : an emerging toxic effect of targeted therapy", Nat Rev Clin Oncol, 6, pp.219~228 (2009)
  69. Demetri GD, "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib(GRID) : an international, multicentre, randomised, placebo-controlled, phase 3 trial", Lancet, 381, pp.295~302 (2013)
  70. Gum O Jung, "A Case of Liver Metastasis of Gastrointestinal Stromal Tumor That Was Resected after Treatment with Imatinib Mesylate and Sunitinib", 한국간담췌외과학회지, 14(4), pp.262~266 (2010), 한국간담췌외과학회
  71. Sawaki A, "Impact of rechallenge with imatinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib", Gastroenterol Res Pract, 2014, pp.342986~ (2014)
  72. Demetri GD, "Imatinib plasma levels are correlated with clinical benefit in patients with unresectable", metastatic gastrointestinal stromal tumors, 2009, pp.27, 3141~3147
  73. Eechoute K, "A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients", Clin Cancer Res, 18, pp.5780~5787 (2012)
  74. Koo DH, "Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor", Cancer Chemother Pharmacol, 75, pp.173~182 (2015)
  75. 윤신교, "Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients", Journal of Korean Medical Science, 28(8), pp.1248~1252 (2013), 대한의학회

관련 논문AI추천

Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea강윤구, 강혜진, 김경미, 김우호, 류민희, 손태성, 양한광, 최동일대한암학회 · Cancer Research and Treatment2012 · 제44권 제2호위장관기질종양의 진단과 치료강윤구, 구동회대한내과학회 · 대한내과학회지2013 · 제85권 제4호Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach: Report of Three Cases김미정, 오지선, Byung Sik Kim, Heung Moon Chang, Jae-Lyun Lee, Jeong Hwan Yook, Min-Hee Ryu, Se Jin Jang, Sung Tae Oh, Tae Won Kim, Yoon-Koo Kang대한암학회 · Cancer Research and Treatment2006 · 제38권 제3호Molecular and Clinicopathological Features of Gastrointestinal Stromal Tumors in Vietnamese PatientsAnh Vu Hoang, Dang Anh Thu Phan, Quoc Dat Ngo, Quoc Thang Pham, Sao Trung Nguyen, Thi Ngoc Ha Hua대한병리학회 · Journal of Pathology and Translational Medicine2019 · 제53권 제6호Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis강소라, 강윤구, 김형돈, 류민희, 방영학, 이형은대한암학회 · Cancer Research and Treatment2022 · 제54권 제4호Clinical Efficacy and Safety of Endoscopic Treatment of Gastrointestinal Stromal Tumors in the Stomach전훈재, Joo Moon Kyung, Kim Seong Min, Kim Won Shik, Lee Beom Jae, Lee Sang Woo, Lee Yeon Ho, Park Jong-Jae, Yoo Ah Young거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제2호

이 간행물의 다른 논문 (29건)

Predictors of Distant Metastasis after Radical Surgery Followed by Postoperative Radiotherapy with or without Chemotherapy for Oropharyngeal Cancer김연실, 이연수, 김지윤, 이윤희, 장지현, 강진형, 유이령, 정미주pp. 1167-1176East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)Ekaterine Alexandris, Pablo Lee, Annamaria Hayden Zimmermann, 강진형, 조은경, Jin-Yuan Shih, 박근칠, Mauro Orlando, 김주항, Tarun Puripp. 1177-1186Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules오동률, 표홍렬, 조원경, 안용찬, 노재명pp. 1187-1195Overexpression of Endoplasmic Reticulum Oxidoreductin 1-α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer설소영, 윤선옥, 홍순원, 김종원, 최승호, 조재용, 김철, 임재윤pp. 1196-1209Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial김여은, Bio Joo, 신상준, 박미숙, 김명진, 안중배pp. 1210-1221
원문 보기